Endometrial Cancers - Healing Genes

Endometrial Cancers

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)

Phase 1


Emory University researchers are recruiting participants for a study on how well an antibody therapy to target cancer in combination with an FDA-approved antibody (Pembrolizumab) to help the immune system identify tumors can shrink advanced tumors of these solid cancers:

  • Pediatric Solid Tumor
  • Germ Cell Tumor
  • Retinoblastoma
  • Hepatoblastoma
  • Wilms Tumor
  • Rhabdoid Tumor
  • Carcinoma
  • Osteosarcoma
  • Ewing Sarcoma
  • Rhabdomyosarcoma
  • Synovial Sarcoma
  • Clear Cell Sarcoma
  • Malignant Peripheral Nerve Sheath Tumors
  • Desmoplastic Small Round Cell Tumor
  • Soft Tissue Sarcoma
  • Neuroblastoma

The investigational therapy will require either just the investigatory antibody therapy, or the combination with Pembrolizumab. Follow up will last at least 56 days.


  • Be 18 years of age or older
  • Have confirmed diagnosis of one of the study’s targeted tumors
  • Not have had prior treatment with an investigational anti-LAG3 therapy


  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Antibody infusion and, if applicable, Pembrolizumab infusion.
  3. Follow up over the next 56 days.


The study site is at Emory University in Atlanta, GA. Map.


Wayne Saville, MD  |  858-480-3410  |  [email protected]

Phuong Lee  |  858-480-3115  |  [email protected]



Xencor, Inc.

ICON plc


Or go online:



Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader